Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...